XIG: FHIR Resources

FHIR IG Statistics: FHIR Resources

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | BNW | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | se | sl | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - All Kinds, Authority Hl7

42,405 resources

By Version

R2: 0
R2B: 0
R3: 2,217
R4: 26,023
R4B: 2,734
R5: 11,207
R6: 224

By Realm

none: 3,411
au: 272
be: 387
ca: 138
ch: 1,482
cl: 469
cr: 45
cz: 384
de: 190
dk: 88
ee: 155
eu: 1,173
fi: 87
fr: 120
in: 29
it: 181
kr: 5
nl: 929
no: 26
nz: 79
pl: 83
se: 22
stt: 116
us: 17,481
uv: 14,773
vn: 107
other: 7

Start Prev Rows 26000 - 26200 Next

Package	Version	Identity	Name/Title	Status	Date	Realm
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1110.72	37 to 42 Plus Weeks Gestation	active	2023-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1110.73	37 to 42 Plus Weeks Gestation	active	2023-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1110.74	37 to 38 Weeks Gestation	active	2023-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1110.75	37 to 38 Weeks Gestation	active	2023-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1110.76	History of Atrial Ablation	active	2022-11	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1110.77	Placenta Accreta Spectrum Previa or Vasa Previa	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1110.78	Placenta Previa	active	2023-11	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.143	Observation Services	active	2021-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.159	All Primary and Secondary Cancer	active	2023-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.161	All Primary and Secondary Cancer	active	2022-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.163	Emergency Department Evaluation	active	2020-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.164	Admit Inpatient	active	2021-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.171	Opioid Use Disorder	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.173	Sickle Cell Disease with and without Crisis SNOMED	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.174	Sickle Cell Disease with and without Crisis ICD	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.175	Sickle Cell Disease with and without Crisis	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.176	Opioid Medication Assisted Treatment (MAT) HCPCS	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.177	Opioid Medication Assisted Treatment (MAT)	active	2025-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.178	Cancer Related Pain ICD 10	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.179	Cancer Related Pain SNOMED	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1111.180	Cancer Related Pain	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.10	Care Experience Preferences at End of Life LOINC	active	2024-02	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.12	Healthcare Agent Ordinality	active	2020-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.14	ADIClauseTypeVS	active	2022-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.17	Preconditions for Treatment Preferences	active	2024-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.22	Advance Directive Document Types	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.23	AD Conditions and Prognosis Scenarios	active	2023-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.26	Healthcare Agent or Advisor Indicator	active	2024-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.27	Initial Treatment portable medical order options	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.28	Cardiopulmonary Resuscitation Order Options	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.30	Cardiopulmonary Resuscitation Order Procedures	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.31	Cardiopulmonary Resuscitation Procedures Grouping	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.32	Additional Portable Medical Order Procedures	active	2025-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.33	Initial Treatment Portable Medical Order Procedures Grouping	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.34	Additional portable medical order Procedures Grouping	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.35	Medically Assisted Nutrition Order Options	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.36	Medically Assisted Nutrition Portable Medical Order Procedures Grouping	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.37	Healthcare Agent Powers	active	2024-11	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.38	Personal Health Goal Options LOINC	active	2025-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.40	Portable Medical Order Document Types	active	2025-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.41	Advance Healthcare Directive Document Types Grouper	active	2025-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1115.8	Treatment Intervention Preferences at End of Life LOINC	active	2025-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.1	Rituximab Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.100	Pathological M Stage M1c	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.101	Pathological N Stage N3	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.102	N Stage pN1a	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.103	N Stage pN1b	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.105	Pathological N Stage pN1mi	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.106	Pathological N Stage N2b	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.107	Pathological N Stage N2a	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.108	Pathological N Stage N2	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.109	Pathological N Stage N1b	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.110	Pathological N Stage N1a	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.112	Pathological N Stage N0	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.114	Pathological T Stage T4d	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.115	Pathological T Stage T4c	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.116	Pathological T Stage T4b	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.117	Pathological T Stage T4a	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.118	Pathological T Stage T4	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.120	N Stage N2C	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.121	T Stage T3c	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.122	T Stage T3b	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.123	T Stage T3a	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.124	Pathological T Stage T3	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.125	T Stage T2c	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.126	T Stage T2b	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.127	T Stage T2a	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.128	Pathological T Stage T2	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.129	Pathological T Stage T1c	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.132	Pathological T Stage T1b	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.135	Pathological T Stage T1a	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.136	Pathological T Stage T1	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.137	Pathological T Stage T1mic	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.139	Pathological T Stage T0	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.142	Cancer Stage III	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.143	Cancer Stage IIIA	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.144	Cancer Stage IIIB	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.145	Cancer Stage IIIC	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.146	Cancer Stage IV	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.147	Cancer Stage IVA	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.148	Cancer Stage IVB	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.149	Cancer Stage IVC	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.151	Cisplatin Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.153	Vinorelbine Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.154	Gemcitabine Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.155	Docetaxel	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.156	Pemetrexed Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.158	Vinblastine Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.160	ECOG Performance Status	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.161	ECOG Performance Status	active	2020-10	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.162	ECOG Performance Status	active	2022-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.164	Karnofsky Performance Status	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.165	Carboplatin Injectable	active	2020-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.166	Paclitaxel	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.168	Doxorubicin Injectable	active	2022-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.169	Irinotecan Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.179	Bevacizumab Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.181	Methotrexate	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.184	Breast Cancer	active	2022-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.185	Breast Cancer	active	2023-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.191	Cancer Stage II	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.192	Cancer Stage IIA	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.193	Cancer Stage IIB	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.194	Pertuzumab Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.196	Ixabepilone Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.197	Goserelin	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.200	Epirubicin Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.202	Ramucirumab Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.204	Letrozole	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.206	Exemestane	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.209	Fluorouracil	active	2024-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.210	Capecitabine Oral	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.222	Aprepitant Oral	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.223	Fosaprepitant Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.255	Colorectal Cancer	active	2021-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.256	Colorectal Cancer	active	2021-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.257	Colorectal Cancer Chemotherapy	active	2023-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.280	Cancer Stage IA	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.281	Cancer Stage IB	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.286	Cancer Stage IIC	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.291	Positive Result	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.292	Negative Result	active	2015-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.300	Pathological N Stage N1C	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.332	Daunorubicin Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.336	Palonosetron Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.341	External Beam Radiotherapy	active	2024-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.349	Metastatic Cancer	active	2023-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.439	T Category	active	2018-05	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.440	N Category	active	2018-05	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.441	M Category	active	2018-05	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.442	TNM Stage Group	active	2018-05	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.449	Opioids	active	2024-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.492	Pharmacological interventions for depression	active	2024-05	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.535	Ovarian Cancer	active	2023-05	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.536	Ovarian Cancer	active	2023-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.537	Fallopian Tube Cancer	active	2022-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.539	Fallopian Tube Cancer	active	2022-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.541	Peritoneal Cancer	active	2022-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.542	Peritoneal Cancer	active	2023-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.547	Cancer Stage 1C	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.555	Gender Female	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.556	Gender Male	active	2024-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.557	Pathological N Stage N3a	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.558	Pathological N Stage N3b	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.560	Rolapitant Oral	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.599	Obinutuzumab Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.600	Ofatumumab Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.602	Neurokinin 1 Receptor Antagonist	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.604	Serotonin Receptor Antagonist	active	2025-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.61	Cetuximab Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.63	Panitumumab Injectable	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.81	Palonosetron Oral	active	2024-12	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.88	Lung Cancer	active	2015-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.89	Lung Cancer	active	2023-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.95	M Stage M0	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.97	Pathological M Stage M1	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.98	Pathological M Stage M1a	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1116.99	Pathological M Stage M1b	active	2024-08	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1125.7	PROMIS Depression Assessment	active	2023-05	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.11	Sleep Apnea	active	2018-05	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.13	Septic Shock due to C. Diff	active	2019-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.15	Body Temperature	active	2022-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.16	Diarrhea Potentially due to CDI	active	2019-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.17	Abdominal Distension	active	2019-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.18	Vomiting potentially due to CDI	active	2019-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.19	Ileus due to infection	active	2019-04	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.20	Clostridium difficile infection	active	2019-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.3	Radiation Therapy Indicators from CPT	active	2017-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.4	Diagnostic Radiology Surrounding Face and Sinus	active	2017-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.5	Ear Surgery Affecting the Tympanic Membrane	active	2017-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.6	Allergic Rhinitis Immunotherapy	active	2017-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.8	Radiology to Head and Sinus	active	2017-06	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1130.9	Immunotherapy For Allergic Rhinitis	active	2022-03	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1136.63	Aortic Dissection or Ruptured Aortic Aneurysm	active	2024-07	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.1	C2S Alcohol Use Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.11	C2S Amphetamine Use Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.12	C2S Cannabis Use Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.13	C2S Cannabis Use Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.14	C2S Cannabis Use Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.15	C2S Cannabis Use DIsorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.16	C2S Cocaine Use Disorder	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.17	C2S Cocaine Use Disorder	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.18	C2S Cocaine Use Disorder	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.19	C2S Hallucinogens	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.2	C2S Alcohol Use Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.20	C2S Hallucinogens	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.21	C2S Hallucinogens	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.22	C2S Hallucinogens	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.23	C2S HIV/AIDS Information Sensitivity	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.24	C2S HIV/AIDS Information Sensitivity	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.25	C2S HIV/AIDS Information Sensitivity	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.26	C2S HIV/AIDS Information Sensitivity	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.27	C2S HIV/AIDS Information Sensitivity	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.28	C2S Inhalants	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.29	C2S Inhalants	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.3	C2S Alcohol Use Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.30	C2S Inhalants	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.32	C2S Mental Health Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.33	C2S Mental Health Disorders	active	2016-09	us
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1142.34	C2S Mental Health Disorders	active	2016-09	us